CIRBP

Across TCGA pan-cancer cohorts, CIRBP mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CIRBP data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CIRBP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CIRBP expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

UCEC, LUAD, and PDAC are the cancer types where CIRBP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	III,IV	0.306	1.000	.008	22	view →
LUAD	OS	Median	II,III,IV	1.000	0.339	<.001	20	view →
PDAC	OS	Tertile	All	0.643	0.451	.016	11	view →
HNSC	DFS	Median	All	0.698	1.000	.020	7	view →
CCRCC	OS	Median	IV	1.000	0.202	.034	6	view →
LSCC	DFS	Median	III,IV	0.490	0.896	.039	3	view →
GBM	OS	Median	All	0.599	0.455	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CIRBP–UCEC (DFS)

Open the UCEC breakdown →